DaVita HealthCare Partners
Inc. DVA, one of the nation's largest and most innovative health care
communities, today announced that two of its business units, DaVita Clinical
Research (DCR) and HealthCare Partners Clinical Research, will merge
capabilities to further expand its extensive clinical research and data
analytics services, specifically in patients with chronic kidney disease (CKD)
and end-stage renal disease (ESRD), as well as primary care and chronic
disease patients treated in an integrated care organization.
www.davitahealthcarepartners.com
The merger allows the two research organizations to offer comprehensive data
analytics capabilities on the longitudinal, de-identified data of
approximately one million active patients receiving care at DaVita HealthCare
Partners centers, including 170,000 U.S. dialysis patients receiving care from
DaVita Kidney Care and 836,000 multi-specialty patients receiving coordinated,
integrated care from HealthCare Partners.
"Since 1997, DaVita Clinical Research has been a leader in kidney-related
trials, epidemiology and data analytics, resulting in better patient
outcomes," said Amy Young, vice president and general manager of DaVita
Clinical Research. "Our clients appreciate the unique understanding of patient
populations that a health care provider-based CRO like DCR can deliver."
Biopharmaceutical and medical device developers can gain insights through
access to the analytics capabilities and understanding of patient data unique
to a health care provider-based clinical research organization.
"HealthCare Partners' extensive patient database is diverse and reflects
real-world evidence in an integrated care organization," said Riya Pulicharam,
MD, medical director of late phase research and clinical outcomes at
HealthCare Partners Clinical Research. "We have conducted clinical trials
across multiple therapeutic areas for more than 10 years, and combining our
clinical research and data analytics capabilities with DCR greatly enhances
our ability to meet additional clients' needs."
The combined entity's capabilities – which include claims, pharmacy and
electronic health record data analysis – offer strategic advantages primed to
benefit recipients of its services. Including the following:
o The combined organization's assets will help boost research-study
enrollment and retention.
o The combined entity offers access to nearly a million primary care and
multi-specialty patients, as well as 280,000 CKD and ESRD patients,
thereby expanding the breadth and depth of the research being conducted.
o This collaboration combines – and builds on – the intellectual, financial
and human resources necessary to support comprehensive analysis of
scenarios ranging from burden-of-illness studies to budget impact models
to market-sizing assessments.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in